Issue 15, 2018

nCVTs: a hybrid smart tumour targeting platform

Abstract

A hybrid drug delivery platform involving the fusion of cell membranes from U937 monocytes and synthetic lipids to create nano-cell vesicle technology systems (nCVTs) is designed. nCVTs are engineered for a targeted approach towards tumour sites by preserving key surface proteins from U937 monocytes, while being amendable to functionalization and loading due to their liposomal components.

Graphical abstract: nCVTs: a hybrid smart tumour targeting platform

Supplementary files

Article information

Article type
Communication
Submitted
22 Nov 2017
Accepted
08 Mar 2018
First published
13 Mar 2018

Nanoscale, 2018,10, 6812-6819

nCVTs: a hybrid smart tumour targeting platform

W. J. Goh, S. Zou, B. Czarny and G. Pastorin, Nanoscale, 2018, 10, 6812 DOI: 10.1039/C7NR08720A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements